The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

Zhang, Huan; Ren, Dianyun; Jin, Xin; Wu, Heshui

doi:10.1186/s12935-020-01558-4

Cited by 28 publications

(27 citation statements)

References 56 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…mGPS levels of 1 or 2 were significantly more often associated with poor OS compared to an mGPS level of 0 (mGPS = 1 vs. mGPS = 0, HR = 1.68, 95% CI: 1.25-2.27, p = 0.001; mGPS = 2 vs. mGPS = 0, HR = 1.90, 95% CI: 1.36-2.67, p < 0.0001). Additional further analyses of 12 studies indicated that mGPS values of 1 or 2 correlated with worse OS in patients receiving chemotherapy (HR = 1.45; 95% CI: 1.05-2.02; p = 0.025) and after pancreatectomy (HR = 1.64; 95% CI: 1.25-2.15; p < 0.0001) [59].…”

Section: Mgpsmentioning

confidence: 94%

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Kapszewicz¹,

Małecka-Wojciesko²

2021

JCM

View full text Add to dashboard Cite

A poor PDAC prognosis is due to a lack of effective treatment and late diagnosis. The early detection of PDAC could significantly decrease mortality and save lives. Idealbiomarkers for PDAC should be cost-effective, detectable in easily accessible biological material, and present in sufficient concentration in the earliest possible phase of the disease. This review addresses newly selected, simple protein biomarkers—new ones such as thrombospondin-2, insulin-linked binding protein 2, lysophosphatidic acid, and autotaxin and conventional ones such as Ca19-9, inflammatory factors, and coagulation factors. Their possible use in the early detection of PDAC, differentiation from benign diseases, prognosis, and treatment response prediction is discussed. We also address the usefulness of possible combinations of biomarkers in diagnostic panels.

show abstract

Section: Mgpsmentioning

confidence: 94%

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Kapszewicz¹,

Małecka-Wojciesko²

2021

JCM

View full text Add to dashboard Cite

show abstract

“…The main advantage of the mGPS is that it utilises two commonly recorded objective measures, making it easy and simple to calculate in a clinical setting. In a meta-analysis of 20 studies, mGPS demonstrated significant overall prognostic power with hazard ratio (HR) of 1.50 for those categorised as high risk by this score versus those with a low risk [ 72 ]. However, most of these studies were conducted in eastern populations, with western population studies showing inconclusive findings (HR: 1.34, p = 0.268).…”

Section: Scoring Systemsmentioning

confidence: 99%

Scoring systems for the management of oncological hepato-pancreato-biliary patients

Coombs

Jordan

Hussain

et al. 2022

Ann Hepatobiliary Pancreat Surg

View full text Add to dashboard Cite

Oncological scoring systems in surgery are used as evidence-based decision aids to best support management through assessing prognosis, effectiveness and recurrence. Currently, the use of scoring systems in the hepato-pancreato-biliary (HPB) field is limited as concerns over precision and applicability prevent their widespread clinical implementation. The aim of this review was to discuss clinically useful oncological scoring systems for surgical management of HPB patients. A narrative review was conducted to appraise oncological HPB scoring systems. Original research articles of established and novel scoring systems were searched using Google Scholar, PubMed, Cochrane, and Ovid Medline. Selected models were determined by authors. This review discusses nine scoring systems in cancers of the liver (CLIP, BCLC, ALBI Grade, RETREAT, Fong’s score), pancreas (Genç’s score, mGPS), and biliary tract (TMHSS, MEGNA). Eight models used exclusively objective measurements to compute their scores while one used a mixture of both subjective and objective inputs. Seven models evaluated their scoring performance in external populations, with reported discriminatory c-statistic ranging from 0.58 to 0.82. Selection of model variables was most frequently determined using a combination of univariate and multivariate analysis. Calibration, another determinant of model accuracy, was poorly reported amongst nine scoring systems. A diverse range of HPB surgical scoring systems may facilitate evidence-based decisions on patient management and treatment. Future scoring systems need to be developed using heterogenous patient cohorts with improved stratification, with future trends integrating machine learning and genetics to improve outcome prediction.

show abstract

“…Apart from inflammation, the nutritional status is also related to the outcomes of cancer patients [ 16 , 17 ]. The modified Glasgow outcome scale (mGPS) [ 18 , 19 ] and C-reactive protein-to-albumin ratio (CAR) [ 20 ], are based on the two important acute phase proteins in SIR, namely C-reactive protein (CRP) and albumin [ 4 ], and are related to the prognosis of cancer patients. Nevertheless, in many treatment centers, CRP is not included as a routine measurement of patient care, which limits its clinical application [ 21 ].…”

Section: Introductionmentioning

confidence: 99%

Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy

et al. 2022

View full text Add to dashboard Cite

Background Systemic inflammatory response (SIR) plays a crucial role in every step of tumorigenesis and development. More recently, the fibrinogen-to-albumin ratio (FAR), an inflammation-based model, was suggested as a prognostic maker for various cancer patients. This research aimed to estimate the prognostic abilities of FAR, neutrophil–lymphocyte ratio (NLR), monocyte-lymphocyte ratio (MLR), platelet– lymphocyte ratio (PLR), and systemic immune–inflammation index (SII) in patients with hepatocellular carcinoma (HCC) subjected to curative hepatectomy. Methods A total of 1,502 cases who underwent hepatectomy for HCC were included. The predictive performances of FAR, NLR, MLR, PLR and SII were assessed with regards to overall survival (OS) and disease-free survival (DFS). The area under the time-dependent receiver operating characteristic curve was used to compare prognostic performances. Results Data revealed that FAR had higher predictive accuracy than other inflammation-based models and alpha-fetoprotein (AFP) in assessing OS and DFS. Indeed, the OS and DFS of patients with high FAR (> 8.9), differentiated by the optimal cut-off value of FAR, were remarkably reduced (p < 0.05 for OS and DFS). Multivariate Cox regression analyses identified that AFP, FAR, clinically significant portal hypertension, tumor size, Barcelona Clinical Liver Cancer staging system, major resection and blood loss were independent indicators for predicting OS and DFS. Furthermore, these patients could be classified according to their FAR into significantly different subgroups, regardless of AFP levels (p < 0.05 for DFS and OS). Similar results were obtained in other inflammation-based prognostic models. Conclusions Compared with NLR, MLR, PLR, SII and AFP, FAR showed significant advantages in predicting survival of HCC patients subjected to liver resection.

show abstract

The prognostic value of modified Glasgow Prognostic Score in pancreatic cancer: a meta-analysis

Cited by 28 publications

References 56 publications

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Simple Serum Pancreatic Ductal Adenocarcinoma (PDAC) Protein Biomarkers—Is There Anything in Sight?

Scoring systems for the management of oncological hepato-pancreato-biliary patients

Preoperative fibrinogen-to-albumin ratio predicts the prognosis of patients with hepatocellular carcinoma subjected to hepatectomy

Contact Info

Product

Resources

About